Last Updated: November 15, 2026

Litigation Details for Forest Laboratories LLC v. Breckenridge Pharmaceutical Inc. (D. Del. 2014)

« Back to Dashboard


Small Molecule Drugs cited in Forest Laboratories LLC v. Breckenridge Pharmaceutical Inc.
The small molecule drug covered by the patents cited in this case is ⤷  Start Trial .

Forest Laboratories LLC v. Breckenridge Pharmaceutical Inc. Litigation Summary, 1:14-cv-01504

Last updated: October 18, 2026

Forest Laboratories LLC sued Breckenridge Pharmaceutical Inc. in the U.S. District Court for the District of Delaware after Breckenridge filed an abbreviated new drug application seeking approval for a generic version of Bystolic, the nebivolol hypertension drug. The case was an ANDA Paragraph IV patent action involving Bystolic-related Orange Book patents.

The litigation appears to have ended by settlement and stipulated dismissal rather than a publicly reported trial judgment. The public record does not establish that Breckenridge received an immediate generic launch right. The principal commercial issue was whether Breckenridge could enter before the expiration of Forest’s Bystolic patent protection.

What drug and generic product were at issue?

The case concerned Bystolic, a branded tablet containing nebivolol hydrochloride. Bystolic is a beta-adrenergic blocker approved by the FDA for treating hypertension. Forest marketed the product in the United States under NDA No. 021742.

Breckenridge’s ANDA sought approval for a generic nebivolol product. Because the ANDA included Paragraph IV certifications against listed patents, Forest filed suit under the Hatch-Waxman Act. The filing of the action triggered the statutory 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii), subject to earlier termination or modification.

Case element Detail
Court U.S. District Court for the District of Delaware
Civil action No. 1:14-cv-01504
Plaintiff Forest Laboratories LLC
Defendant Breckenridge Pharmaceutical Inc.
Product Bystolic, nebivolol hydrochloride
Regulatory pathway ANDA Paragraph IV litigation
Branded NDA NDA No. 021742
Filed 2014
Disposition Settlement-related stipulated dismissal
Trial judgment No publicly reported merits judgment in the Breckenridge docket

Bystolic was later associated with Actavis and Allergan after Forest’s acquisition by Actavis in 2014. The ownership and commercialization history matters because patent enforcement, regulatory submissions and settlement rights could involve successor entities even when Forest remained the named plaintiff in the original action.

What patents protected Bystolic in the Breckenridge case?

The Bystolic patent estate included patents covering nebivolol, methods of using nebivolol to treat hypertension and pharmaceutical compositions. The principal patents associated with the Bystolic ANDA litigation included the following:

Patent General subject matter Approximate listed expiration Litigation relevance
U.S. Patent No. 6,545,040 Nebivolol and treatment of hypertension 2021, subject to applicable term adjustments Core Bystolic patent
U.S. Patent No. 8,618,164 Nebivolol treatment methods and related pharmaceutical use Approximately 2029-2030 Later-expiring method-of-use protection
U.S. Patent No. 8,628,799 Nebivolol pharmaceutical composition and dosage-form claims Approximately 2029 Formulation and composition protection

Patent scope and expiration dates must be separated from the commercial availability of a generic. FDA Orange Book listings can include multiple patents with different claim categories, while a generic applicant may challenge some patents and carve out approved uses associated with others.

What formulations were protected?

The Bystolic estate was not limited to the active ingredient in isolation. It included protection directed to pharmaceutical compositions and the use of nebivolol in oral dosage forms. These patents created additional barriers after the earliest active-ingredient or method patent approached expiration.

Formulation claims can be commercially important even where a generic applicant can avoid infringement of a method-of-use patent. A generic company may attempt to:

  • Use a different excipient system.
  • Market only strengths or indications that avoid a listed method claim.
  • Submit a Section viii statement carving out patented indications.
  • Challenge the validity or enforceability of composition claims under Paragraph IV.

The public record for Breckenridge does not provide a reported claim-construction or infringement ruling establishing how the court would have applied these patents to Breckenridge’s proposed product.

When did Forest file the Bystolic patent lawsuit?

Forest filed the action in 2014 after receiving notice of Breckenridge’s Paragraph IV certifications. The case was assigned civil action No. 1:14-cv-01504 in the District of Delaware.

The statutory filing deadline in an ANDA case is generally 45 days after receipt of the Paragraph IV notice. A timely suit permits the branded company to obtain the Hatch-Waxman 30-month stay. The stay delays FDA approval, not necessarily commercial launch, and can end earlier through settlement, court judgment or other statutory mechanisms.

The Breckenridge action was one of several Bystolic-related cases filed against generic applicants. Parallel cases involving other defendants addressed overlapping patents and helped shape the overall generic-entry risk for nebivolol.

What was the Paragraph IV challenge?

Breckenridge’s ANDA Paragraph IV certification represented that the relevant Bystolic patents were invalid, unenforceable or would not be infringed by the proposed generic product. The certification allowed Breckenridge to challenge patent protection before the patents expired.

A Paragraph IV filing creates two separate consequences:

  1. It gives the brand company a basis to sue for patent infringement before FDA approval.
  2. It can give the first qualifying ANDA filer 180-day generic exclusivity under the Hatch-Waxman Act, although eligibility depends on the statutory facts and subsequent regulatory events.

The Breckenridge docket does not establish that Breckenridge obtained commercial first-filer exclusivity. Its case should therefore be analyzed as a generic-entry challenge, not as evidence that Breckenridge controlled the U.S. generic launch window.

How did the Breckenridge case end?

The case ended through a settlement-related dismissal rather than a reported trial decision. The public docket does not disclose all commercial terms, including any authorized-entry date, royalty arrangement, supply agreement or restrictions on launch.

That distinction is material. A dismissal does not establish that:

  • The asserted patents were valid.
  • Breckenridge infringed.
  • Forest prevailed on the merits.
  • Breckenridge was barred from entering until patent expiration.
  • FDA approval was permanently blocked.

In pharmaceutical patent cases, settlement documents may be filed under seal or summarized only in a publicly filed stipulation. The operative public docket can therefore show termination without disclosing the economic terms that determine the actual generic-entry date.

Did the case produce a patent-validity decision?

No reported merits decision in the Breckenridge action establishes a final ruling on validity, infringement or enforceability. Separate Bystolic litigation involving other ANDA defendants generated more substantive decisions concerning the patent estate.

The Federal Circuit later addressed Bystolic-related patent issues in Forest Laboratories LLC v. Sigmapharm Laboratories LLC, 918 F.3d 928 (Fed. Cir. 2019). That decision concerned the validity of Bystolic-related patent claims and did not convert the Breckenridge dismissal into a merits determination.

For portfolio analysis, the distinction is important:

Question Breckenridge case
Was there a trial? No publicly reported trial
Was patent validity adjudicated? No publicly reported final merits ruling
Was infringement adjudicated? No publicly reported final merits ruling
Was the case dismissed? Yes, following settlement-related resolution
Are settlement terms public in full? No
Does the dismissal prove patent strength? No
Does the dismissal prove generic weakness? No

What was the Orange Book status of Bystolic?

Bystolic was listed in the FDA Orange Book with patents directed to the drug and its approved uses. The Orange Book is the primary regulatory source for determining which patents a brand company identified to FDA for an approved product.

Orange Book listing does not itself establish patent validity or infringement. It does, however, determine the patent certifications an ANDA applicant must address. A listed patent can produce a Paragraph IV dispute, a Section viii carve-out or a certification that approval must wait until patent expiration.

For Bystolic, the relevant risk categories were:

  • Composition patents covering nebivolol dosage forms.
  • Method-of-use patents covering treatment of hypertension.
  • Later-issued patents extending protection beyond the earliest Bystolic patent.
  • Potential pediatric exclusivity or patent-term adjustments affecting the effective regulatory date.

The FDA Orange Book should be reviewed by historical publication date when assessing the 2014 case. Current listings can differ from the listings that existed when Breckenridge filed its ANDA and when Forest initiated the lawsuit.

When did Bystolic lose exclusivity?

Bystolic’s exclusivity consisted of separate regulatory and patent components.

The core patent expiration associated with Bystolic was approximately 2021 for U.S. Patent No. 6,545,040. Later patents listed for Bystolic extended potential patent protection into the late 2020s or early 2030s, depending on the claim set, patent-term adjustment and the specific patent being evaluated.

Protection type Approximate period Effect
NDA approval 2007 Established the approved branded product
Core patent protection Through approximately 2021 Primary early generic barrier
Later formulation or method patents Into approximately 2029-2030 and beyond Potential secondary barriers
ANDA litigation 2014 onward Delayed approval through litigation and settlement
Generic competition After resolution of patent and regulatory barriers Dependent on FDA approval and settlement terms

Regulatory exclusivity and patent exclusivity are different. Even after FDA exclusivity ends, a generic may remain blocked by unexpired patents. Conversely, patent expiration does not guarantee immediate generic sales if FDA approval, manufacturing readiness or settlement restrictions remain unresolved.

Which companies challenged the Bystolic patents?

Forest filed Bystolic-related cases against multiple generic applicants, including Breckenridge, Apotex and Sigmapharm. The defendants pursued ANDA approval through Paragraph IV certifications.

The competitive landscape included:

  • Forest Laboratories, the original branded plaintiff.
  • Actavis and later Allergan, as Forest successors or commercial affiliates.
  • Breckenridge Pharmaceutical.
  • Apotex.
  • Sigmapharm Laboratories.
  • Other ANDA applicants involved in related Bystolic litigation.

Parallel litigation can affect the commercial result. One defendant’s settlement may permit entry on a particular date, while another defendant’s trial judgment may establish patent validity or infringement. A settlement in one action does not automatically determine the rights of unrelated ANDA filers.

What generic-entry risks did the settlement create?

The primary risk was delayed or controlled entry rather than permanent exclusion. A settlement could have included an agreed launch date, a license, a supply arrangement, a royalty, a no-challenge provision or other commercial terms.

Because the public Breckenridge docket does not disclose the full settlement terms, the most defensible conclusion is that the case removed the immediate litigation proceeding without producing a public merits ruling. The settlement therefore reduced litigation uncertainty but did not eliminate the need to evaluate:

  • Remaining Orange Book patents.
  • Other generic defendants’ litigation outcomes.
  • FDA approval status.
  • Whether Breckenridge received a licensed early-entry date.
  • Whether the settlement included a product-launch restriction.
  • Whether later patents could support a new infringement action.

How strong was the Bystolic patent estate?

The estate was commercially meaningful because it combined an earlier core patent with later method and formulation patents. Its strength was reduced by the absence of a merits decision in the Breckenridge case and by the vulnerability inherent in obviousness and claim-scope challenges against an established small-molecule beta blocker.

The estate’s practical strength can be characterized as follows:

Factor Assessment
Core active-ingredient protection Strong commercial value but time-limited
Method-of-use protection Potentially useful against full-label generic marketing
Formulation protection Could block a specific dosage form if claim scope covered the ANDA product
Litigation leverage Significant because of the 30-month stay
Validity certainty in Breckenridge Not established by a final decision
Settlement leverage High enough to resolve the case without trial
Long-term exclusivity Depended on later patents and their enforceability

The Federal Circuit’s later Bystolic-related litigation shows that the patent estate required claim-specific analysis. A broad statement that "Bystolic patents were upheld" or "Bystolic patents were invalidated" would not accurately describe the record.

Did biosimilar law affect the case?

No. Bystolic is a conventional small-molecule drug, and Breckenridge pursued an ANDA rather than a biosimilar application under the Biologics Price Competition and Innovation Act.

The relevant pathway was Hatch-Waxman:

  • ANDA approval under Section 505(j).
  • Paragraph IV patent certifications.
  • Potential 30-month stay.
  • Possible 180-day first-filer exclusivity.
  • Section viii indication carve-outs.

Biosimilar concepts such as reference-product exclusivity, interchangeability and biologic patent dance procedures were not applicable.

What licensing or settlement information is public?

The docket reflects a settlement-related resolution, but the complete economic terms are not publicly available in the ordinary case record. No public evidence establishes a separate licensing transaction between Forest and Breckenridge beyond the litigation settlement.

Potential settlement provisions in an ANDA case typically include:

  • A defined generic launch date.
  • A license to listed patents.
  • Royalty or other payment terms.
  • Restrictions on marketing or manufacturing.
  • Allocation of 180-day exclusivity rights.
  • Covenants not to sue.
  • Confidentiality obligations.

Only terms filed publicly or disclosed in regulatory materials can be treated as confirmed. The Breckenridge docket does not support a precise statement of the agreed launch date or payment structure.

Key Takeaways

  • Forest sued Breckenridge in Delaware in 2014 over an ANDA Paragraph IV challenge to Bystolic, or nebivolol hydrochloride.
  • The case involved Forest’s Orange Book-listed Bystolic patent estate, including U.S. Patent Nos. 6,545,040, 8,618,164 and 8,628,799.
  • The action ended through settlement-related dismissal rather than a reported merits judgment.
  • The public record does not establish the complete settlement terms or a confirmed Breckenridge launch date.
  • The core Bystolic patent expired approximately in 2021, while later method and formulation patents potentially extended protection into the late 2020s and beyond.
  • The dispute was a Hatch-Waxman ANDA case, not a biosimilar action.
  • Separate Bystolic litigation, including Forest Laboratories LLC v. Sigmapharm Laboratories LLC, provides more substantive guidance on patent validity than the Breckenridge docket.
  • The Breckenridge dismissal should not be treated as proof that the patents were valid, infringed or enforceable.

FAQs About Forest Laboratories v. Breckenridge Pharmaceutical

What was Forest Laboratories v. Breckenridge about?

It was a Hatch-Waxman patent case concerning Breckenridge’s proposed generic version of Bystolic, the nebivolol hypertension drug.

Was Breckenridge allowed to launch generic Bystolic?

The public case record does not establish the full settlement terms or a confirmed launch date for Breckenridge.

Did Forest win the case?

The case ended by settlement-related dismissal. There was no publicly reported trial judgment establishing that Forest won on patent validity or infringement.

Was Bystolic protected by formulation patents?

Yes. The Bystolic patent estate included composition and dosage-form claims in addition to method-of-use protection.

Is Bystolic subject to biosimilar competition?

No. Bystolic is a small-molecule drug. Competition proceeds through the ANDA generic-drug pathway rather than the biosimilar pathway.

References

  1. U.S. District Court for the District of Delaware. (2014). Forest Laboratories LLC v. Breckenridge Pharmaceutical Inc., No. 1:14-cv-01504.

  2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov

  3. U.S. Food and Drug Administration. (2007). Bystolic prescribing information, NDA No. 021742.

  4. Forest Laboratories LLC v. Sigmapharm Laboratories LLC, 918 F.3d 928 (Fed. Cir. 2019).

  5. U.S. Patent No. 6,545,040. (2003). Nebivolol for the treatment of hypertension. United States Patent and Trademark Office.

  6. U.S. Patent No. 8,618,164. (2013). Nebivolol pharmaceutical compositions and methods of use. United States Patent and Trademark Office.

  7. U.S. Patent No. 8,628,799. (2014). Nebivolol pharmaceutical compositions. United States Patent and Trademark Office.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.